Scarica l'app Stockscreener
13.40
2.37%
0.31
Dopo l'orario di chiusura:
13.43
0.03
+0.22%
Precedente Chiudi:
$13.09
Aprire:
$13.08
Volume 24 ore:
77,294
Relative Volume:
0.63
Capitalizzazione di mercato:
$117.01M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-670.00
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
-4.83%
1M Prestazione:
+59.14%
6M Prestazione:
-22.28%
1 anno Prestazione:
-48.06%
Intervallo 1D:
$12.69
$13.67
Intervallo di 1 settimana:
$11.15
$14.78
Portata 52W:
$6.53
$29.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Confronta MCRB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
13.40 | 108.19M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
What risks could impact Seres Therapeutics Inc. stock performanceExplosive portfolio gains - jammulinksnews.com
Will Seres Therapeutics Inc. stock benefit from AI tech trendsHigh-yield capital appreciation - jammulinksnews.com
What institutions are buying Seres Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com
What drives Seres Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional
Is Seres Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - Autocar Professional
Seres Therapeutics Inc. Stock Analysis and ForecastFree Consultation - Autocar Professional
What analysts say about Seres Therapeutics Inc. stockSuperior capital gains - jammulinksnews.com
Seres Therapeutics announces leadership transition - MSN
Seres Therapeutics Soars 10.98% on Leadership Transition - AInvest
Seres Therapeutics stock jumps after naming co-CEOs By Investing.com - Investing.com Canada
Seres Therapeutics (MCRB) Announces Transition in Executive Lead - GuruFocus
Seres Therapeutics Announces Leadership Transition - The Manila Times
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times
Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates - Quiver Quantitative
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st
what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser
How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser
What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser
How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser
Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest
5 Best Microbiome Companies (July 2025) - Securities.io
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener
Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com Nigeria
FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus
Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):